Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice

Cancer Chemotherapy and Pharmacology

Volumn 43, Issue 1, 1999, Pages 1-7

  Newman, Mary S ^a   Colbern, Gail T ^a   Working, Peter K ^a   Engbers, Charles ^a   Amantea, Michael A ^a  

^a ALZA CORPORATION   (United States)

Author keywords

C26 colon; Cisplatin; Lewis lung; SPI 077 ; Stealth liposomes

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CISPLATIN DERIVATIVE; DOXORUBICIN; LIPOSOME; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CANCER CHEMOTHERAPY; COLON CARCINOMA; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

ALGORITHMS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, LEWIS LUNG; CISPLATIN; COLONIC NEOPLASMS; DRUG CARRIERS; INJECTIONS, INTRAVENOUS; LIPOSOMES; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; RATS; SPECTROPHOTOMETRY, ATOMIC; TISSUE DISTRIBUTION;

EID: 0032958135     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050855     Document Type: Article

References (22)

1. 1. Allen TM, Newman MS, Woodle MC, Mayhew E, et al (1995) Pharmacokinetics and anti-tumor activity of vincristine encapsulated in sterically stabilized liposomes. Int J Cancer 62: 199
2. 2. Amantea MA, Forrest A, Northfelt DW, Mamelok R (1997) Population pharmacokinetics and pharmacodynamics of pegylated liposomal doxorubicin in pateints with AIDS-related Kaposi's sarcoma. Clin Pharmacol Ther 61: 301
3. 3. Comis RL (1994) Cisplatin: the future. Semin Oncol 21: 109
4. 4. D'Argenio, Schumitzky A (1979) A program package for simulaiton and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 9: 115
5. 5. Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM (1988) Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 133: 95
6. 6. Gabizon A, Catane R, Uziely B (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54: 987
7. 7. Hacker MP (1991) Toxicity of platinum-based anticancer drugs. In: Powis G, and Hacker MP (ed) The toxicity of anticancer drugs. McGraw-Hill, New York, p 82
8. 8. Kelland RL, McKeage MJ (1994) New platinum agents. A comparison in ovarian cancer. Drugs Aging 5: 85
9. 9. Kurihara N, Kubota T, Hoshiya Y, Otani Y, et al (1996) Antitumor activity of cis-diamminedichloroplatinum (II) against human tumor xenografts depends on its area under the curve in nude mice. Clin Res 26: 436A
10. 10. Lasic DD (1996) Doxorubicin in sterically stabilized liposomes. Nature 380(6574): 561
11. 11. McKeage MJ, Boxall F, Jones M (1994) Lack of neurotoxicity or oral bis-acetat-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in comparison to cisplatin and tetraplatin. Cancer Res 54: 629
12. 12. McKeage MJ, Mistry P, Ward J, Boxall FE, et al (1995) A phase I and pharmacological study of an oral platinum complex (JM216): dose-dependent pharmacokinetics with single dose administration. Cancer Chemother Pharmacol 36: 451
13. 13. Nagai N, Ogata H (1997) Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo. Cancer Chemother Pharmacol 40: 11
14. 14. Northfelt DW, Martin FJ, Working PK, Volberding PA, et al (1996) Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 36: 55
15. 15. Ogilvie GK, Fettman MJ, Jameson VJ, Walters LM, et al (1992) Evaluation of a one-hour saline diuresis protocol for administration of cisplatin to dogs. Am J Vet Res 53: 1666
16. 16. Schellens JHM, Meerum T, Groenewegen G, et al (1998) Phase I and pharmacologic study of SPI-77, a novel Stealth® liposomal encapsulated formulation of cisplatin (CDDP). Eighty-ninth Annual Meeting, Proceedings of American Association for Cancer Research, New Orleans
17. 17. Schilder RJ, LaCreta FP, Perez RP (1994) Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC363812) administered on a day 1 and 8 schedule. Cancer Res 54: 709
18. 18. Steerenberg PA, Storm G, deGroot G, Claessen A, et al (1988) Liposomes as a drug carrier system for cis-diamminedichloro-platinum(II). II. Antitumor resistance in vivo, induction of drug resistance, nephrotoxicity and Pt distribution. Cancer Chemother Pharmacol 21: 299
19. 19. Vaage J, Donovan D, Uster P, Working P (1997) Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma. Br J Cancer 75: 482
20. 20. Woodle MC, Lasic DD (1992) Sterically stabilized liposomes. Biochem Biophys Acta 1113: 171
21. 21. Woodle MC, Newman MS, Working PK (1995) Biological properties of sterically stabilized liposomes. In: Lasic DD, Martin FM (ed) Stealth liposomes. CRC Press, Boca Raton, p 103
22. 22. Wu NZ, Dewhirst MW (1993) Measure of tissue uptake of intravenously injected macromolecules using fluorescence video-microscopy. Microvasc Res 46: 231